early-dialysis-av-fistula-graft-surgery In the first few months of hemodialysis, one additional provider visit per month increased the probability of AV fistula or graft surgery by nearly 5%. When ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Placement of an arteriovenous fistula in patients with chronic kidney disease not on dialysis can ...

Please provide your email address to receive an email when new articles are posted on . Published findings indicated that while patients 77 years or older had lower likelihoods of arteriovenous ...

During the 9-year study period from November 1992 to October 2001, 1,601 initial hemodialysis accesses were placed, consisting of 741 prosthetic grafts (46.3%), 690 simple AVF (43.1%), and 170 basilic ...

A two-day conference on controversies in Dialysis Access Asia-Pacific (CiDAAP) began at the Hyatt Regency in Gurgaon. Debates, discussions and a competitive challenge among interventional radiologists ...

CINCINNATI—Researchers at the University of Cincinnati (UC) and the Cincinnati Department of Veterans Affairs (VA) Medical Center have received funding to study the care processes that lead to ...

The University of Alabama at Birmingham (UAB) Kidney-Pancreas Transplant faculty have busy elective dialysis access practices. Almost 1,000 operative cases are performed each year. A strong emphasis ...

The odds of starting hemodialysis with an arteriovenous fistula are 31% lower for women compared with men. Despite the “fistula first” campaign, women, especially black women, are less likely than men ...

Health care providers can now take advantage of a new video series to help them talk with patients about preparing for dialysis treatments, the National Institutes of Health announced today. The eight ...

—Early nephrology referral and attention to the trajectory of estimated glomerular filtration rate (eGFR) could help clinicians and their patients with end-stage kidney disease (ESKD) achieve better ...

DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at ...